المؤلفون: Mpoudi-Etame, M., Sanchez, T. T., Bassega, P. O., Olinga, J., /Pelloquin, Raphael, Foalem, M., Njonkep, C., Mimbe, E., Varloteaux, M., Tongo, M., Lamare, N., /Peeters, Martine, Reynes, J., Delaporte, E., Koulla-Shiro, S., Kouanfack, C., NAMSAL ANRS Study Group

جغرافية الموضوع: CAMEROUN

Relation: https://www.documentation.ird.fr/hor/fdi:010085919; oai:ird.fr:fdi:010085919; Mpoudi-Etame M., Sanchez T. T., Bassega P. O., Olinga J., Pelloquin Raphael, Foalem M., Njonkep C., Mimbe E., Varloteaux M., Tongo M., Lamare N., Peeters Martine, Reynes J., Delaporte E., Koulla-Shiro S., Kouanfack C., NAMSAL ANRS Study Group. Dolutegravir versus efavirenz-400 as first-line ART in Cameroon : week 192 data of NAMSAL trial. 2022, 25 (suppl. 3), p. 15

الاتاحة: https://www.documentation.ird.fr/hor/fdi:010085919